Echocardiography may be at the vanguard for early and rapid detection of heart issues indicative of Duchenne muscular ...

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

After deaths and FDA setbacks, Sarepta abandoned LGMD gene therapy, leaving families desperate and patients without ...

Managing osteoporosis and bone health in Duchenne muscular dystrophy occurs in a high-risk environment for fractures due to disease-related loss of muscle and movement, adverse effects of ...

The city of Rockford dedicated a memorial plaque to one of their own, who died in November to a form of muscular dystrophy.

The FDA’s shift on Elevidys sends a message: boldness, scientific rigor and urgency are essential in confronting rare ...

For adults with Duchenne muscular dystrophy, swallowing-related impairments are associated with age, inspiratory muscle strength, and autonomic dysfunction, say the results of a new study. CMR ...

The Duchenne muscular dystrophy market is witnessing steady growth driven by advancements in gene therapies, exon-skipping drugs, and corticosteroid alternatives. Increasing diagnosis rates ...

This September, the Muscular Dystrophy Association (MDA) is launching its milestone #MDAstrong campaign during a historic moment for the organization: its 75th anniversary. The campaign reframes what ...

Global Duchenne Muscular Dystrophy Drugs Market Report 2023: Sector is Expected to Reach $4 Billion by 2028 at a CAGR of 11.88% - ResearchAndMarkets.com May 18, 2023 07:21 AM Eastern Daylight Time ...